Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025.
Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS from Multiple ILD SubtypesIn a featured oral presentation, Johanna Schaub, Ph.D., Director of Translational Sciences at Pliant Therapeutics, discussed an evaluation of the antifibrotic activity of bexotegrast in fibrotic human precision-cut lung slices (PCLS) generated from non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (ILD) patient lung explants. Results showed that bexotegrast, a dual inhibitor of αVβ6/αVβ1 integrins, reduced expression of genes related to TGF-β signaling and fibrogenesis in alveolar type 1 (AT1) cells and multiple fibroblast subpopulations.
Plasma Proteome Analysis Reveals Shared and Unique Biomarkers of ILD SubtypesIn a poster presentation, Erine Budi, Ph.D., Senior Scientist II Translational Biology at Pliant Therapeutics, reviewed a comparative analysis assessing circulating plasma biomarkers of ILD in healthy subjects and patients with idiopathic pulmonary fibrosis (IPF), rheumatoid arthritis-ILD (RA-ILD), and scleroderma associated-ILD (SSc-ILD). Results identified biomarkers consistently dysregulated across multiple ILD subtypes that could assist in informing clinical decision making in ILD.
Single-Cell Profiling Demonstrates the Antifibrotic Effects of Bexotegrast on Pathologic Lung Cell Populations in the Presence and Absence of Background TherapyIn a poster presentation, Mahru An, Ph.D., Director of Translational Sciences at Pliant Therapeutics, reviewed a single-nuclei RNAseq analysis of fibrotic human precision-cut lung slices comparing the pharmacodynamic effects of bexotegrast, a dual inhibitor of αVβ6 and αVβ1 integrins, alone, or in combination with nintedanib. Results showed that treatment with bexotegrast or nintedanib displayed distinct cell-specific pharmacodynamic profiles. In addition, bexotegrast alone, or in the presence of nintedanib, significantly reduced the expression of type I collagen and other profibrotic genes in aberrant basaloid cells (αVβ6-expressing) and fibroblasts (αVβ1-expressing), while treatment with nintedanib alone did not.
The presentation and posters presented at the 2025 ATS Conference are available by accessing the links above or on Pliant's website under the Publications section at https://pliantrx.com/publications.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is undergoing evaluation for the treatment of idiopathic pulmonary fibrosis, or IPF. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency in IPF. Pliant is conducting a Phase 1 study for PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn, and Facebook.
Investor and Media Contact:
Christopher KeenanVice President, Investor Relations and Corporate CommunicationsPliant Therapeutics, Inc.ir@pliantrx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Mitchell Quain Bought 9.6% More Shares In AstroNova
Whilst it may not be a huge deal, we thought it was good to see that the AstroNova, Inc. (NASDAQ:ALOT) Independent Director, Mitchell Quain, recently bought US$91k worth of stock, for US$9.05 per share. However, it only increased their shares held by 9.6%, and it wasn't a huge purchase by absolute value, either. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. In the last twelve months, the biggest single purchase by an insider was when Lead Independent Director Richard Warzala bought US$161k worth of shares at a price of US$8.07 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$9.01. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price. In the last twelve months AstroNova insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction! Check out our latest analysis for AstroNova AstroNova is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket. Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that AstroNova insiders own 7.9% of the company, worth about US$5.5m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing! It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on AstroNova stock. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we've found that AstroNova has 3 warning signs (2 don't sit too well with us!) that deserve your attention before going any further with your analysis. Of course AstroNova may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Prosperity Bancshares (NYSE:PB) shareholders have earned a 7.5% CAGR over the last five years
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd like to see the share price move up more than the market average. But Prosperity Bancshares, Inc. (NYSE:PB) has fallen short of that second goal, with a share price rise of 22% over five years, which is below the market return. Looking at the last year alone, the stock is up 15%. So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. Over half a decade, Prosperity Bancshares managed to grow its earnings per share at 1.8% a year. This EPS growth is slower than the share price growth of 4% per year, over the same period. This suggests that market participants hold the company in higher regard, these days. That's not necessarily surprising considering the five-year track record of earnings growth. You can see below how EPS has changed over time (discover the exact values by clicking on the image). We know that Prosperity Bancshares has improved its bottom line lately, but is it going to grow revenue? Check if analysts think Prosperity Bancshares will grow revenue in the future. When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. As it happens, Prosperity Bancshares' TSR for the last 5 years was 43%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments! It's nice to see that Prosperity Bancshares shareholders have received a total shareholder return of 19% over the last year. And that does include the dividend. That's better than the annualised return of 7% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand Prosperity Bancshares better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Prosperity Bancshares , and understanding them should be part of your investment process. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
18 minutes ago
- Yahoo
Founder Group says ‘will not be impacted' by solar power tax credits wind down
Founder Group (FGL) assures investors that the Company will not be impacted by a U.S. Senate panel's proposed wind down of solar power tax credits by 2028. 'Founder Group operates primarily in Malaysia and doesn't have operations in the U.S. Therefore, the Company should not be affected by the sentiments currently causing selloffs of U.S. solar power stocks,' said Lee Seng Chi, CEO. 'Although we are listed on Nasdaq and trade alongside U.S. solar power stocks, we will not be impacted by the possible elimination of those tax credits. Our revenue is predominantly generated from the Malaysian market hence we are not affected by the changes suggested by President Donald Trump's tax cut and spending bill. In the near future, our expansion will focus on regional expansion in Southeast Asia only. Expansion to the U.S. is not in our current plans.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on FGL: Disclaimer & DisclosureReport an Issue Founder Group signs MOU with GCL to cooperate on renewable energy projects Founder Group secures additional contracts with solar installation companies Founder Group files to sell 11.75M ordinary shares for holders Founder Group Secures $10 Million Investment Agreement with Avondale Capital Founder Group Limited Terminates Securities Purchase Agreement Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
